These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Lines C; Challenor J; Traub M Br J Clin Pharmacol; 1995 Mar; 39(3):235-42. PubMed ID: 7619662 [TBL] [Abstract][Full Text] [Related]
6. Pentagastrin test for anxiety--psychophysiology and personality. Radu D; Ahlin A; Svanborg P; Lindefors N Psychopharmacology (Berl); 2003 Mar; 166(2):139-45. PubMed ID: 12529809 [TBL] [Abstract][Full Text] [Related]
7. Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. Abelson JL; Nesse RM; Vinik AI Biol Psychiatry; 1994 Jul; 36(2):84-96. PubMed ID: 7524696 [TBL] [Abstract][Full Text] [Related]
8. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks. Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820 [TBL] [Abstract][Full Text] [Related]
9. Thyrotropin-releasing hormone: a potential comparator for the panicogenic effects of pentagastrin and CCK? Coupland N; Malizia A; Bailey J; Nutt D Biol Psychiatry; 1996 Mar; 39(6):465-6. PubMed ID: 8679797 [No Abstract] [Full Text] [Related]
10. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Koszycki D; Zacharko RM; Le Melledo JM; Young SN; Bradwejn J Biol Psychiatry; 1996 Oct; 40(7):648-55. PubMed ID: 8886299 [TBL] [Abstract][Full Text] [Related]
11. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Zwanzger P; Eser D; Aicher S; Schüle C; Baghai TC; Padberg F; Ella R; Möller HJ; Rupprecht R Neuropsychopharmacology; 2003 May; 28(5):979-84. PubMed ID: 12700707 [TBL] [Abstract][Full Text] [Related]
12. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375 [TBL] [Abstract][Full Text] [Related]
13. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Wiedemann K; Jahn H; Yassouridis A; Kellner M Arch Gen Psychiatry; 2001 Apr; 58(4):371-7. PubMed ID: 11296098 [TBL] [Abstract][Full Text] [Related]
14. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Ströhle A; Holsboer F; Rupprecht R Neuropsychopharmacology; 2000 Mar; 22(3):251-6. PubMed ID: 10693152 [TBL] [Abstract][Full Text] [Related]
15. Response to pentagastrin after acute phenylalanine and tyrosine depletion in healthy men: a pilot study. Coupland N; Zedkova L; Sanghera G; Leyton M; Le Mellédo JM J Psychiatry Neurosci; 2001 May; 26(3):247-51. PubMed ID: 11394194 [TBL] [Abstract][Full Text] [Related]
16. Effects of propranolol on symptom and endocrine responses to pentagastrin. Khan S; Liberzon I; Abelson JL Psychoneuroendocrinology; 2004 Oct; 29(9):1163-71. PubMed ID: 15219640 [TBL] [Abstract][Full Text] [Related]
17. Anxiogenic effects of the CCK(B) agonist pentagastrin in humans and dose-dependent increase in plasma C-peptide levels. Radu D; Ahlin A; Svanborg P; Lindefors N Psychopharmacology (Berl); 2002 Jun; 161(4):396-403. PubMed ID: 12073167 [TBL] [Abstract][Full Text] [Related]
18. Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. McCann UD; Morgan CM; Geraci M; Slate SO; Murphy DL; Post RM Neuropsychopharmacology; 1997 Dec; 17(6):360-9. PubMed ID: 9397424 [TBL] [Abstract][Full Text] [Related]
19. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. van Megen HJ; Westenberg HG; den Boer JA; Haigh JR; Traub M Psychopharmacology (Berl); 1994 Apr; 114(3):449-55. PubMed ID: 7855203 [TBL] [Abstract][Full Text] [Related]
20. Relationship between respiratory, endocrine, and cognitive-emotional factors in response to a pharmacological panicogen. Lyubkin M; Giardino ND; Abelson JL Depress Anxiety; 2010 Nov; 27(11):1011-6. PubMed ID: 20721903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]